Opioid-Withdrawal Beverage Seller Latest Target Of FDA-FTC Joint Enforcement
This article is powered by The Rose Sheet
Executive Summary
While essentially all products labeled as dietary supplements but marketed with claims to treat diseases or illnesses could be targets of FTC enforcement against unsubstantiated advertising, FDA warnings to firms linked to those products generally don't discuss violations of FTC rules. But the warning to Up-Inya Beverages, like firms previously identified as making opioid-withdrawal claims, included an explanation of how it's in FTC's crosshairs, too.
You may also be interested in...
Opioid Drug Sales Online Draw US FDA Warnings, Prompt Summit Meeting
At June 27 "Online Opioid Summit," FDA officials, pharma sales researchers, and industry stakeholders will discuss collaborating for stronger impact against the opioid crisis by reducing the availability of illicit products online."The internet is virtually awash in illegal narcotics and we’re going to be taking new steps to work with legitimate internet firms to voluntarily crack down on these sales," says Commissioner Scott Gottlieb.
Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue
FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.